Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.52 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192229 | 0.88 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL30450055 | 0.88 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL30450381 | 0.88 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL1193293 | 0.88 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL1192578 | 0.85 | EGLN1 (0.58) | EGLN1RHEB | |
| SCHEMBL30449418 | 0.83 | EGLN1 (0.55) | EGLN1GAAHTTMEN1NPC1 | |
| SCHEMBL1192548 | 0.83 | EGLN1 (0.55) | EGLN1GAAHTTMEN1NPC1 | |
| SCHEMBL1192961 | 0.82 | NOTUM (0.46) | EGLN1GAAHTTMEN1NPC1 | |
| SCHEMBL1192221 | 0.81 | EGLN1 (0.52) | EGLN1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1192403 | 0.81 | EGLN1 (0.54) | EGLN1HTTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-01 | — | — | US | disclosed |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-02 | — | — | US | disclosed |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-20160168127-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| US-9073923-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-07 | — | — | US | disclosed |
| US-8865713-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-01-02 | — | — | US | disclosed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 10/4885RHEB 1790/4885GAA 65/4885 |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | EGLN1 5/4885RHEB 1692/4885GAA 126/4885 |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
| US-20160168127-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885RHEB 1716/4885GAA 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.